Human Genome Sciences, Inc.

Epitomics, Inc.

Mendel Biotechnology, Inc.

Apexigen, Inc.

Other

University of California

University of Michigan

The General Hospital Corporation

Qyuns Therapeutics Co., Ltd.

Epotimics, Inc.

Guo-Liang Yu

Jian Ni

Craig A Rosen

Reiner L Gentz

Reinhard Ebner

Patrick J Dillon

Steven M Ruben

Ping Feng

Weimin Zhu

Oliver J Ratcliffe

Jacqueline E Heard

Jose Luis Riechmann

Cai-Zhong Jiang

Omaira Pineda

Gregory A Endress

Yongke Zhang

Luc Adam

Marsha L Pilgrim

Haodong Li

T Lynne Reuber

Robert A Creelman

Yaohuang Ke

Ping Fan

Arnold N DuBell, Iii

Pierre Broun

Henrik S Olsen

Ann MeeJin Ferrie

Paul E Young

John M Greene

Jun Zhang

Laurie A Brewer

Kenneth C Carter

James S Keddie

Daniel R Soppet

Fernando Jose Rebelo Do Couto

Yanggu Shi

Jing-Shan Hu

Kimberly A Florence

Kristin Beth Hendricks

Carrie L Fischer

Ying-Fei Wei

Frederick M Ausubel

Jeannine D Gocayne

Roxanne Duan

Michael Nicholas Mindrinos

Jeffrey Y Su

Brian J Staskawicz

Douglas Dahlbeck

Fumiaki Katagiri

Andrew F Bent

Bradley K Sherman

Barbara N Kunkel

S Ellen Wallace

Yifan Zhai

Stephen Ullrich

Paul A Moore

Yi Li

Vishva M Dixit

Claire M Fraser

William A Haseltine

Roderick W Kumimoto

David William Lafleur

James Z Zhang

John M Salmeron

Daniel P Bednarik

Hla Kyaw

Barbara J Baker

Volker Haake

Zhizhen Zeng

Raymond R Samaha

Pierre E Broun

Jeffrey Ellis

Lynne Reuber

Luc J Adam

Arnold N Dubell

Fernando Jose Couto

Neal I Gutterson

Karen S Century

Peter P Repetti

Stacey Ellen Wallace

Michael Fromm

Charles Florence

Sum Wai Pierre Lee

Xiaodong Yang

Bernadetta Nardelli

Karin Vroom

Pedro Alfonso

Fouad Janat

Daniel P Soppet

Daniel R Bednarik

Jiar Ni

Arnold Dubell

Lynne T Reuber

The present invention provides high affinity anti-CD40 monoclonal antibodies and related compositions, which may be used in any of a variety of therapeutic methods for the treatment of cancer and other diseases.

Anti-CD40 antibodies

Provided are methods for identifying T-cell receptors that bind to an antigen in primates. In certain embodiments, the methods comprise: sequencing the cDNA prepared from a combined population of T-cells to obtain a plurality of T-cell receptor alpha chain sequences and a plurality of T-cell receptor beta chain sequences; grouping the obtained alpha chain sequences into alpha chain groups based on their CDR3 sequences; grouping the obtained beta chain sequences into beta chain groups based on their CDR3 sequences; pairing the alpha chain groups with the beta chain groups based on the number of alpha chain or beta chain sequences in each group; pairing one alpha chain sequence and one beta chain sequence in each paired alpha chain group and beta chain group; and testing candidate T-cell receptor comprising the paired alpha chain and beta chain sequences for binding to the antigen.

Method for identifying antigen-specific T cell receptors in primate

The invention provides a method for identifying positions of an antibody that can be modified without significantly reducing the binding activity of the antibody. In many embodiments, the method involves identifying a substitutable position in a parent antibody by comparing its amino acid sequence to the amino acid sequences of a number of related antibodies that each bind to the same antigen as the parent antibody. The amino acid at the substitutable position may be substituted for a different amino acid without significantly affecting the activity of the antibody. The subject methods may be employed to change the amino acid sequence of a CDR without significantly reducing the affinity of the antibody of the antibody, in humanization methods, or in other antibody engineering methods. The invention finds use in a variety of therapeutic, diagnostic and research applications.

Methods for screening and engineering antibodies

The present invention provides anti-RANKL monoclonal antibodies and related compositions, which may be used in any of a variety of therapeutic methods for the treatment of rheumatoid arthritis and other diseases.

Anti-RANKL antibodies and methods of use

Provided are methods for identifying antibodies that bind to an antigen in primates. In certain embodiments, the methods comprise: sequencing the cDNA prepared from a combined population of antibody-producing B-cells to obtain a plurality of antibody heavy chain sequences and a plurality of antibody light chain sequences; grouping the obtained antibody heavy chain sequences into heavy chain groups based on their CDR3 sequences; grouping the obtained antibody light chain sequences into light chain groups based on their CDR3 sequences; pairing the heavy chain groups with the light chain groups based on the number of antibody heavy chain or light chain sequences in each group; pairing one antibody heavy chain sequence and one light chain sequence in each paired heavy chain group and light chain group; and testing candidate antibodies comprising the paired heavy chain and light chain sequences for binding to the antigen.

Method for identifying antigen-specific antibodies in primate

The invention relates to plant transcription factor polypeptides, polynucleotides that encode them, homologs from a variety of plant species, and methods of using the polynucleotides and polypeptides to produce transgenic plants having advantageous properties compared to a reference plant. Sequence information related to these polynucleotides and polypeptides can also be used in bioinformatic search methods and is also disclosed.

Polynucleotides and polypeptides in plants

In certain embodiments, the method may comprise: a) obtaining the antibody sequences from a population of B cells; b) grouping the antibody sequences to provide a plurality of groups of lineage-related antibodies; c) testing a single antibody from each of the groups in a bioassay and, after the first antibody has been identified, d) testing further antibodies that are in the same group as the first antibody in a second bioassay. In another embodiment, the method may comprise: a) testing a plurality of antibodies obtained from a first portion of an antibody producing organ of an animal; b) obtaining the sequence of a first identified antibody; c) obtaining from a second portion of said antibody producing organ the sequences of further antibodies that are related by lineage to said first antibody; and, c) testing the further antibodies in a second bioassay.

Method for identifying lineage-related antibodies

Anti-CD40 antibodies and methods of use

The present invention provides anti-KDR monoclonal antibodies and related compositions, which may be used in any of a variety of therapeutic methods for the treatment of a variety of cancers, rheumatoid arthritis, diabetic retinopathy and other diseases associated with aberrant VEGF or KDR expression and/or activity.

Anti-KDR antibodies and methods of use

An antibody that binds TNF &#x3b1; and neutralizes its activity is provided. In certain cases, the antibody comprises: a) a heavy chain variable domain comprising an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO. 1, and b) a light chain variable domain comprising an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID No. 2.

Anti-TNF&#x3b1; antibody

Methods of inhibiting proliferation of CD40-expressing cancer cells with anti-CD40 antibodies

A method of obtaining nucleic acid encoding a plurality of antibodies is provided. In certain embodiments, the method comprises obtaining from an immunized animal nucleic acid encoding the amino acid sequence of the heavy and light chains of a second antibody that binds to the antigen as a first antibody and differs in amino acid sequence to the first antibody, wherein the obtaining is done by amplification using: i. a first primer pair that includes oligonucleotides are complementary to CDR-encoding regions first antibody.

CDR-anchored amplification method

Growing community of inventors

Berkeley, CA, United States of America

Guo-Liang Yu